NASDAQ:CRSP

CRISPR Therapeutics Stock Forecast, Price & News

$122.27
-2.50 (-2.00 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$119.39
$124.64
50-Day Range
$109.22
$161.89
52-Week Range
$76.71
$220.20
Volume1.04 million shs
Average Volume1.81 million shs
Market Capitalization$9.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28
30 days | 90 days | 365 days | Advanced Chart
Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


CRISPR Therapeutics logo

About CRISPR Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

792nd out of 2,215 stocks

Biological Products, Except Diagnostic Industry

115th out of 211 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CRISPR Therapeutics?

Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CRISPR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, July 26th 2021.
View our earnings forecast for CRISPR Therapeutics
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings data on Monday, April, 26th. The company reported ($1.51) EPS for the quarter, missing the consensus estimate of ($1.47) by $0.04. The company earned $0.54 million during the quarter, compared to analysts' expectations of $4.99 million. CRISPR Therapeutics had a negative net margin of 35,630.97% and a negative trailing twelve-month return on equity of 27.42%.
View CRISPR Therapeutics' earnings history
.

How has CRISPR Therapeutics' stock price been impacted by COVID-19?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has increased by 182.5% and is now trading at $122.27.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRSP?

18 brokerages have issued 1 year price objectives for CRISPR Therapeutics' shares. Their forecasts range from $110.00 to $210.00. On average, they expect CRISPR Therapeutics' stock price to reach $160.38 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:
  • Dr. Rodger Novak, Founder, Chairman & Pres (Age 54)
  • Dr. Samarth Kulkarni, CEO & Director (Age 42, Pay $1.18M)
  • Mr. Michael John Tomsicek, Chief Financial Officer (Age 55, Pay $678.16k)
  • Dr. Lawrence Otto Klein Ph.D., Chief Operating Officer (Age 38, Pay $675k)
  • Mr. James R. Kasinger, Gen. Counsel & Sec. (Age 49, Pay $648.93k)
  • Dr. Tony W. Ho M.D., Exec. VP of R&D (Age 55, Pay $908k)
  • Mr. Shaun Foy, Founder
  • Dr. Emmanuelle Marie Charpentier, Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello, Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan, Scientific Founder

Who are some of CRISPR Therapeutics' key competitors?

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Traynor Capital Management Inc. (0.02%), Boyd Watterson Asset Management LLC OH (0.01%), Stratos Wealth Partners LTD. (0.00%), Compagnie Lombard Odier SCmA (0.00%), Hodges Capital Management Inc. (0.00%) and Golden Green Inc. (0.00%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics
.

Which major investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Stratos Wealth Partners LTD.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics
or view top insider-selling stocks.

Which major investors are buying CRISPR Therapeutics stock?

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Traynor Capital Management Inc., Boyd Watterson Asset Management LLC OH, Hodges Capital Management Inc., Compagnie Lombard Odier SCmA, Prentiss Smith & Co. Inc., Sound Income Strategies LLC, North Star Investment Management Corp., and Golden Green Inc..
View insider buying and selling activity for CRISPR Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $122.27.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $9.26 billion and generates $720,000.00 in revenue each year. The company earns $-348,860,000.00 in net income (profit) each year or ($5.29) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 410 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]


This page was last updated on 7/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.